Skip to main content
Funded Studies

Therapeutic Efficacy of IC 100 in Small Models

Study Rationale: Parkinson’s disease (PD) is characterized by the loss of neurons in the brain. Despite available treatments, no approved therapy can slow disease progression. Data in humans and small models indicate that inflammation in the brain may contribute to PD, however, this has not been clearly defined. Recent data have shown that activation of inflammatory pathways contributes to the pathology of PD. We have a recently developed monoclonal antibody that penetrates the brain and may inhibit this inflammation. 

Hypothesis: Chronic inflammation is a key process that drives Parkinson’s disease. By blocking this chronic inflammation, degeneration of neurons observed in PD may be reduced. 

Study Design: The goal of this project is to investigate the therapeutic effects of inhibiting inflammation in a small model of PD. In this study we will induce PD in small models and determine if a novel monoclonal antibody developed to treat brain inflammation improves disease outcomes. 

Impact on Diagnosis/Treatment of Parkinson’s disease: This study will shed light on the contribution of inflammation and its associated effects on development of PD, opening a potential avenue of treatment with a novel monoclonal antibody (an antibody made by cloning a unique white blood cell) to slow progression of PD symptoms. 

Next Steps for Development: This is one of a series of studies that could support the eventual clinical assessment of this monoclonal antibody in patients with PD.  


  • Nicholas A. LaBella, Jr

    Weston, FL United States

Discover More Grants

Search by Related Keywords

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.